Loading organizations...
§ Private Profile · Austin, TX, USA
SubjectWell is a technology company.
SubjectWell delivers patient recruitment solutions for clinical trials, utilizing a technology platform to match individuals with suitable studies. Its core offerings, including a vast patient network and Patient Companions, streamline recruitment for sponsors, CROs, and research sites. This approach accelerates enrollment via sophisticated patient matching and engagement strategies globally across therapeutic areas.
Founded in 2012 by Ivor Clarke, Joel Lucas, Kip McKenzie, and Rick Westervelt, SubjectWell addressed recognized challenges in clinical trial patient recruitment. Identifying bottlenecks in participant identification, the founders developed a marketplace model. Their collective expertise shaped a predictable, patient-centric system to overcome inefficiencies.
The company serves pharmaceutical sponsors, CROs, and research sites, connecting patients with personalized trial opportunities. SubjectWell's vision is to advance global healthcare by transforming patient access and involvement in clinical research. It expedites medical innovation through timely enrollment, fostering efficient new therapy development and better patient experiences.
SubjectWell has raised $47.0M across 3 funding rounds.
SubjectWell has raised $47.0M in total across 3 funding rounds.
SubjectWell has raised $47.0M across 3 funding rounds. Most recently, it raised $35.0M Series B in October 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2022 | $35M Series B | Skip Fleshman | Andreessen Horowitz, Asset Management Ventures, Astanor Ventures, CRV, Founders Fund, Future Shape, Greylock, Healthy Ventures, O'Reilly AlphaTech Ventures, Tribe Capital, TWO Sigma Ventures, ULU Ventures, Zigg Capital, Aaron Peterman, Anne Wojcicki, Bart Swanson, Halle Tecco, Thorsten Wirkes, Geekdom Fund, Windham Venture Partners | Announced |
| Jun 1, 2019 | $10M Series A | Adam Fine | Astanor Ventures, Founders Fund, Future Shape, Healthy Ventures, ULU Ventures, Zigg Capital, Aaron Peterman, Bart Swanson, Geekdom Fund | Announced |
| Feb 1, 2018 | $2M Seed | — | Astanor Ventures, Founders Fund, Future Shape, Healthy Ventures, ULU Ventures, Zigg Capital, Aaron Peterman, Bart Swanson | Announced |
SubjectWell has raised $47.0M in total across 3 funding rounds.
SubjectWell's investors include Skip Fleshman, Andreessen Horowitz, Asset Management Ventures, Astanor Ventures, CRV, Founders Fund, Future Shape, Greylock, Healthy Ventures, O'Reilly AlphaTech Ventures, Tribe Capital, Two Sigma Ventures.
SubjectWell is a venture-backed technology company building a patient-centric platform for clinical trial recruitment and commercial solutions in the $100 billion sector.[2][1] It connects patients and caregivers to trials via the SubjectWell+ platform, serving sponsors, CROs, sites, and brand marketers by solving inefficiencies in patient matching, enrollment delays, and site burdens across 600+ therapeutic areas, including rare diseases and oncology.[3][4][1] With a network of 13M+ patients, it has completed 1,400+ studies, served 8,800+ sites, and accelerated enrollment by 30% while helping recoup $40B in losses.[3][1]
The platform emphasizes precision through AI/ML predictive models, dynamic matching, and real-time insights, paired with services like clinically trained Patient Companions in 22 languages across 36 countries.[4][3] This drives global reach in 102 countries, transforming patient access to breakthroughs and speeding medical research.[3][2]
SubjectWell was founded in 2012 by two serial entrepreneurs on their third successful startup, experienced in digital marketplaces for consumer matching.[2] They identified flaws in traditional patient recruitment—inefficient, one-trial-at-a-time advertising that left patients unaware of opportunities and caused trials to fall behind schedule.[2] Pivoting to a clinical trials marketplace, they enabled broad education on trial benefits, multi-trial screening, and high-touch matching, achieving early traction with over 115 pharma/biotech companies across 175 therapeutic areas.[2]
This approach evolved into the robust SubjectWell+ platform, expanding from U.S.-focused efforts to global scale with 13M+ patients and services like Patient Companions.[1][3]
SubjectWell rides the clinical trial digitization trend, addressing a $100B market plagued by delays—trials often miss schedules due to poor patient awareness and matching.[2][3] Timing aligns with post-pandemic demand for faster recruitment amid rising rare disease and oncology studies, amplified by AI advancements in healthcare data.[4] Market forces like regulatory pressures for diversity, global trials, and $40B annual losses from delays favor its scalable, predictive tech and network effects.[3]
It influences the ecosystem by enabling sponsors/CROs/sites to hit timelines, boosting research velocity and patient access—humanizing trials via education and companions while setting a marketplace standard for precision recruitment.[1][2]
SubjectWell is poised to dominate as AI-driven healthtech scales, potentially expanding its data warehouse for deeper predictive analytics and commercial tools beyond trials.[4][3] Trends like decentralized trials, personalized medicine, and global regulatory harmonization will amplify its network advantages, targeting even rarer conditions and emerging therapies. Its influence may evolve into a full healthcare opportunity marketplace, further disrupting silos and accelerating breakthroughs—cementing its role from recruitment innovator to ecosystem transformer, much like its founders' prior marketplace successes.[2]